Liver Cancer

Latest News

The FDA gives orphan drug designation to ezurpimtrostat, an investigational autophagy inhibitor that may benefit patients with hepatocellular carcinoma.
Ezurpimtrostat Receives FDA Orphan Drug Designation for Liver Cancer Subtype

February 10th 2023

The FDA gives orphan drug designation to ezurpimtrostat, an investigational autophagy inhibitor that may benefit patients with hepatocellular carcinoma.

According to findings from a phase 2 clinical study, futibatinib may achieve benefit in patients with intrahepatic cholangiocarcinoma harboring FGFR2¬ rearrangements.
Futibatinib Yields Clinical Benefit in FGFR2+ Intrahepatic Cholangiocarcinoma

February 5th 2023

Adjuvant atezolizumab plus bevacizumab may effectively combat recurrence after surgery in patients with early-stage hepatocellular carcinoma.
Data Favor Adjuvant Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma

January 23rd 2023

Newer Therapies Show Superior Benefit in Retrospective Data on First-Line HCC
Newer Therapies Show Superior Benefit in Retrospective Data on First-Line HCC

January 22nd 2023

Patients diagnosed with locally advanced, hepatocellular carcinoma experience benefit in overall survival, progression-free survival, and time to disease progression following treatment with sorafenib and stereotactic body radiation therapy.
Sorafenib/SBRT Yields OS Benefit in Locally Advanced Hepatocellular Carcinoma

January 21st 2023

Video Interviews

More News